Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Galalae, Razvan M; Martinez, Alvaro; Mate, Tim; Mitchell, Christina; Edmundson, Gregory; Nuernberg, Nils; Eulau, Stephen; Gustafson, Gary; Gribble, Michael; Kovács, Gyoergy

Galalae, Razvan M; Martinez, Alvaro; Mate, Tim; Mitchell, Christina; Edmundson, Gregory; Nuernberg, Nils; Eulau, Stephen; Gustafson, Gary; Gribble, Michael; Kovács, Gyoergy.

Affiliation

Galalae RM; Clinic for Radiation Therapy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. galalae@onco.uni-kiel.de

Int J Radiat Oncol Biol Phys ; 58(4): 1048-55, 2004 Mar 15.

Article in En | MEDLINE | ID: mdl-15001244

Subject(s)

Androgen Antagonists/therapeutic use; Brachytherapy/methods; Prostatic Neoplasms/drug therapy; Prostatic Neoplasms/radiotherapy; Radiotherapy, Conformal/methods; Aged; Analysis of Variance; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Male; Middle Aged; Radiotherapy Dosage; Regression Analysis; Risk Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy / Radiotherapy, Conformal / Androgen Antagonists Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male / Middle aged Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2004 Document type: Article Affiliation country: Germany Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links